Masitinib

Drug Profile

Masitinib

Alternative Names: AB-1010; Masican; Masipro; Masitinib mesilate; Masitinib mesylate; Masiviera

Latest Information Update: 23 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AB Science
  • Class Antiasthmatics; Antineoplastics; Antirheumatics; Benzamides; Nootropics; Piperazines; Pyridines; Small molecules; Thiazoles
  • Mechanism of Action Colony stimulating factor inhibitors; Focal adhesion protein-tyrosine kinase inhibitors; Platelet-derived growth factor receptor antagonists; Protein tyrosine kinase inhibitors; Proto oncogene protein c-kit inhibitors; Type 3 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mastocytosis; Amyotrophic lateral sclerosis; Gastric cancer; Gastrointestinal stromal tumours; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Amyotrophic lateral sclerosis; Mastocytosis
  • Phase III Alzheimer's disease; Asthma; Colorectal cancer; Gastrointestinal stromal tumours; Malignant melanoma; Multiple myeloma; Multiple sclerosis; Pancreatic cancer; Peripheral T-cell lymphoma; Prostate cancer
  • Phase II/III Crohn's disease; Ovarian cancer; Progressive supranuclear palsy
  • Phase II Breast cancer; Chronic obstructive pulmonary disease; Head and neck cancer; Mood disorders; Non-small cell lung cancer; Parkinson's disease
  • Phase I/II Gastric cancer; Glioblastoma; Hepatocellular carcinoma; Oesophageal cancer
  • Preclinical Stroke
  • No development reported Psoriasis
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 19 Apr 2018 The Committee for Medicinal Products for Human Use of the EMA adopts negative opinion for approval of masitinib for Amyotrophic lateral sclerosis in European Union
  • 19 Oct 2017 Preclinical data in Amyotrophic lateral sclerosis released by AB Science
  • 15 Sep 2017 Committee for Medicinal Products for Human Use (CHMP) recommends the refusal of the marketing authorisation for masitinib for Mastocytosis in European Union as the benefits of anamorelin do not outweigh the potential risks
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top